Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Grabs Rights to US Biotech’s Metabolic Cancer Drug
June 26, 2019
- Poxel/Sumitomo’s Imeglimin Delivers Again, This Time in Insulin Combo Study
June 26, 2019
- Daiichi Sankyo to Return Rights to 4 Diagnostic Imaging Agents to GE Healthcare
June 26, 2019
- Opdivo Shows No Significant Difference vs Sorafenib in OS for 1st-Line HCC Use in Global PIII: BMS
June 26, 2019
- MSD’s Zerbaxa Now Available in Japan 4 Months after NHI Price Listing; Ensuring Stable Supply
June 26, 2019
- Days after Japan OK, FDA Spurns Daiichi Sankyo’s Quizartinib
June 25, 2019
- Shionogi Hooks Up with Ferrer to Promote Rizmoic in Spain
June 25, 2019
- Shionogi Licenses Mulpleta, Epertinib to China’s Eddingpharm Group
June 25, 2019
- 2018 Global Pharma Market Valued at US$1.09 Trillion, Humira Resounding No. 1: IQVIA
June 24, 2019
- ViiV Supporting Campaigns to Raise HIV Diagnosis Rate in Japan: CEO
June 24, 2019
- Ex-Otsuka Kagaku Exec Becomes PeptiStar’s New President
June 24, 2019
- Lantus/Lyxumia Combo Shows Effectiveness in Japan PIII: Sanofi
June 21, 2019
- Royalty Feud with Nobel Laureate Takes Center Stage at Ono Shareholder Meeting
June 21, 2019
- Japan IBD Market Projected at 155.8 Billion Yen in 2027: Fuji Keizai
June 20, 2019
- Fujifilm to Invest 300 Million Yen in Shimane Univ. Spinoff Regenerative Medicine Biotech
June 20, 2019
- Japan Approves 1st Avastin Biosimilar
June 19, 2019
- Eisai, Harvard Researchers Develop Novel Anticancer Agent Derived from Total Synthesis of Halichondrin
June 19, 2019
- Keytruda Momentum Unabated at ASCO, Snapshot of 5 Checkpoint Inhibitors
June 18, 2019
- 281 Apply for Torii’s Voluntary Redundancy Program
June 18, 2019
- Cold Agglutinin Disease Patients Have High Thromboembolism Event Risk: Sanofi Database Study
June 18, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…